Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers

Fig. 4

Schematic mechanism of Icaritin treatment induced anti-cancer and immune-modulation activities via IL-6/JAK2/Stat3-associated protein networking in hepatocellular carcinoma (HCC). a. Icaritin induced anti-tumour cell proliferation, anti-inflammation and immune modulation activities. b. Simplified sketch for the potential cytokine-mediated network interactions between tumour cells and immune cells in the tumour microenvironment (modified from Dr. Fisher DT et al. Semin Immunol. 2014; 26(1): 38–47. doi:https://doi.org/10.1016/j.smim.2014.01.008)

Back to article page